Impact of Disease Biology and Bridging Strategy on Outcomes After CAR-T Cell Therapy in Relapsed/Refractory Multiple MyelomaIrene Straßl, Maria‐Theresa Krauth, Annkristin Heine et al.|Transplantation and Cellular Therapy|2026Cited by 0
Glofitamab in Heavily Pretreated Mantle Cell Lymphoma Patients: A Multicenter Real‐World Case SeriesNatalia Rotter, Thomas Melchardt, Markus Raderer et al.|eJHaem|2026Cited by 0
Long-term follow-up of ruxolitinib pre-approval use in acute and chronic graft-versus-host diseaseRaphael Loisl, Johannes Clausen, Anna Bauhofer et al.|Annals of Hematology|2026Cited by 0